

WHO operational handbook on tuberculosis

Module 4: Treatment

**Drug-resistant
tuberculosis treatment**



World Health
Organization

WHO operational handbook on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment

ISBN 978-92-4-000699-7 (electronic version)

ISBN 978-92-4-000700-0 (print version)

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. (<http://www.wipo.int/amc/en/mediation/rules/>)

Suggested citation. WHO operational handbook on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Design by Inis Communication.

WHO operational handbook on tuberculosis

Module 4: Treatment

**Drug-resistant
tuberculosis treatment**

Contents

Acknowledgements.....	iv
Abbreviations.....	v
1. Introduction.....	1
2. Commonly used terms and key definitions in drug-resistant TB treatment.....	2
3. Key considerations in drug-resistant TB treatment	5
3.1 Access to DST.....	5
3.2 Safety monitoring and management, provision of patient support and management of comorbidities	7
3.3 Options in drug-resistant TB treatment regimens.....	7
4. Regimen for rifampicin-susceptible and isoniazid-resistant TB.....	9
4.1 Eligibility	9
4.2 Composition and duration of the regimen.....	10
4.3 Considerations for implementation.....	11
4.4 Treatment monitoring	12
5. The shorter all-oral bedaquiline-containing regimen for MDR/RR-TB.....	14
5.1 Eligibility	14
5.2 Composition and duration of the regimen.....	16
5.3 Key subgroups.....	17
5.4 Treatment monitoring.....	18
5.5 Using modified all-oral shorter MDR-TB regimens under operational research.....	19
6. Longer regimens for MDR/RR-TB.....	20
6.1 Eligibility	22
6.2 Medicines used in longer MDR-TB treatment regimens.....	23

6.3 Composition of the longer MDR-TB regimens.....	31
6.4 Prolonged use of bedaquiline and concurrent use of bedaquiline and delamanid.....	36
6.5 Dosage of the longer MDR-TB regimen components.....	36
6.6 Duration of the longer MDR-TB regimens.....	37
6.7 Key subgroups.....	38
6.8 Treatment monitoring	39
7. The bedaquiline, pretomanid and linezolid (BPaL) regimen for MDR-TB with additional fluoroquinolone resistance.....	41
7.1 Eligibility	42
7.2 Composition and duration of the regimen.....	43
7.3 Key subgroups.....	45
7.4 Considerations for implementation	46
7.5 Treatment monitoring.....	47
8. Adjuncts to MDR-TB treatment.....	51
8.1 Surgery in treatment of M/XDR-TB.....	51
8.2 Use of corticosteroids.....	52
8.3 Use of immunomodulators.....	52
8.4 Treatment of HIV coinfecting MDR/RR-TB patients.....	53
9. Patient support to enable adherence to treatment.....	54
10. Programmatic implementation of MDR-TB regimens.....	56
References.....	60
Annex I: Dosage by weight band for medicines used in multidrug-resistant TB regimens, adults and children.....	68



Acknowledgements

This operational handbook was prepared by Fuad Mirzayev, Linh Nguyen, Medea Gegia and Kerri Viney under the overall direction of Matteo Zignol and Tereza Kasaeva. Contributions and inputs were also provided by Dennis Falzon, Ernesto Jaramillo, Alexei Korobitsyn, Annemieke Brands, Sabine Verkuijl and Annabel Baddeley at the WHO Global TB Programme.

The WHO Global TB Programme gratefully acknowledges the contributions of all experts and reviewers who were involved in the production of the operational handbook. The external review group was composed of Vineet Bhatia (WHO SEARO, India), Charles Daley (National Jewish Health, USA), Christopher Gilpin (IOM, Switzerland), Rafael Laniado Laborin (National TB Programme, Mexico), Ben Marais (The University of Sydney School of Medicine, Australia), YaDiul Mukadi (USAID, USA), Mamel Quelapio (KNCV, The Philippines), Maria Rodriguez (National TB programme, Dominican Republic), Sarabjit Singh Chadha (FIND, India), Fraser Wares (KNCV, The Netherlands) and Askar Yedilbayev (WHO EURO, Denmark).

The following individuals and organizations have contributed to the review of the handbook by responding to public call for comments to the draft Chapter 5 of the Companion Handbook to the WHO Guidelines on Management of Drug-Resistant Tuberculosis in July 2019: Jay Achar (MSF, Belgium), Muhammad Asif (technical adviser to National TB Programme, Myanmar), Draurio Barreira Cravo Neto (Unitaid, Switzerland), Vineet Bhatia (WHO SEARO, India), Yuliya Chorna (TB Europe Coalition, Ukraine), Kelly Dooley (Johns Hopkins University School of Medicine, USA), Magdy Fawzy (National TB Programme, Egypt), Abdul Ghafoor (National TB Programme, Pakistan), Elmira Gurbanova (Lung Clinic, University of Tartu, Estonia), Edwin H. Herrera Flores (Peruvian Society of Pneumology, Peru), Domingo Juan Palmero (Hospital F.J. Muniz, Argentina), Gary Maartens (University of Cape Town, South Africa), Lawrence Mbuagbaw (St Joseph's Healthcare Hamilton, Canada), Ignacio Monedero-Recuero (The Union, France), Ernesto Montoro (WHO AMRO, USA), Suneetha Narreddy (Apolo Hospitals, India), Alberto Piubello (The Union, Niger), Maria Rodriguez (National TB Programme, Dominican Republic), Alena Skrahina (National TB Programme, Belarus), Shenjie Tang (Beijing Chest Hospital, China), Hoang Thanh Thuy (National TB Programme, Viet Nam), Ye Tun (Thingankyun General Hospital, Myanmar), Francis Varaine (MSF, France), Interactive Research and Development (Pakistan), KNCV (The Netherlands), Partners In Health (USA), The Sentinel Project, Treatment Action Group (USA) and USAID (USA).

The design and layout of this operational handbook was made possible by funding provided by USAID and Unitaid.

Abbreviations

aDSM	active tuberculosis drug safety monitoring and management
AE	adverse event
AIDS	acquired immunodeficiency syndrome
aOR	adjusted odds ratio
ART	antiretroviral therapy
ARV	antiretroviral
AST	aspartate aminotransferase
BPaL	a regimen of bedaquiline, pretomanid and linezolid for 6–9 months
CNS	central nervous system
CSF	cerebrospinal fluid
DOT	directly observed treatment
DRS	drug-resistance surveillance
DR-TB	drug-resistant tuberculosis
DST	drug susceptibility testing
ECG	electrocardiography
FDC	fixed-dose combination (of medicines)
GDF	Global Drug Facility
GDG	guideline development group
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HIV	human immunodeficiency virus
Hr-TB	confirmed rifampicin-susceptible, isoniazid-resistant tuberculosis
IPD	individual patient data
LPA	line probe assay
LTBI	latent tuberculosis infection
MDR-TB	multidrug-resistant tuberculosis
MDR/RR-TB	multidrug- or rifampicin-resistant tuberculosis
MGIT	mycobacteria growth indicator tube
MIC	minimum inhibitory concentration
NTP	national tuberculosis programme
PAS	<i>p</i> -aminosalicylic acid
PI	protease inhibitor
PK/PD	pharmacokinetics/pharmacodynamics
PLHIV	people living with HIV
RCT	randomized controlled trial

RR-TB	rifampicin-resistant tuberculosis
SAE	serious adverse event
TB	tuberculosis
VOT	video observed treatment
WHO	World Health Organization
XDR-TB	extensively drug-resistant tuberculosis

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24538

